Cargando…
Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells
Human REV7 (also known as MAD2L2 and MAD2B) is involved in DNA repair, cell cycle regulation, gene transcription, and carcinogenesis. In this study, we evaluated the expression of REV7 in epithelial ovarian cancer (EOC) and analyzed the association between its expression and chemosensitivity in ovar...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317831/ https://www.ncbi.nlm.nih.gov/pubmed/24597627 http://dx.doi.org/10.1111/cas.12390 |
_version_ | 1782355738583105536 |
---|---|
author | Niimi, Kaoru Murakumo, Yoshiki Watanabe, Naoki Kato, Takuya Mii, Shinji Enomoto, Atsushi Asai, Masato Asai, Naoya Yamamoto, Eiko Kajiyama, Hiroaki Shibata, Kiyosumi Kikkawa, Fumitaka Takahashi, Masahide |
author_facet | Niimi, Kaoru Murakumo, Yoshiki Watanabe, Naoki Kato, Takuya Mii, Shinji Enomoto, Atsushi Asai, Masato Asai, Naoya Yamamoto, Eiko Kajiyama, Hiroaki Shibata, Kiyosumi Kikkawa, Fumitaka Takahashi, Masahide |
author_sort | Niimi, Kaoru |
collection | PubMed |
description | Human REV7 (also known as MAD2L2 and MAD2B) is involved in DNA repair, cell cycle regulation, gene transcription, and carcinogenesis. In this study, we evaluated the expression of REV7 in epithelial ovarian cancer (EOC) and analyzed the association between its expression and chemosensitivity in ovarian clear cell carcinoma (CCC) cells. Expression of REV7 in human EOC tissues was assessed by immunohistochemical staining. Expression was detected in the majority of EOCs (92.0%) with especially high levels of expression frequently observed in CCCs (73.5%) compared with that of non-CCCs (53.4%). Enhanced immunoreactivity to REV7 was associated with poor prognosis represented by reduced progression-free survival in advanced stage (stage II–IV) EOC as assessed using Kaplan–Meier curves and log–rank tests. The effects of REV7 knockdown on cell proliferation and chemosensitivity in CCC cells were also analyzed in vitro and in vivo. Knockdown of REV7 in CCC cells decreased cell proliferation without affecting cell cycle distribution. Additionally, the number of apoptotic cells and DNA damaged cells were increased after cisplatin treatment. In a nude mouse tumor xenograft model, inoculated REV7-knockdown tumors showed significantly reduced tumor volumes after cisplatin treatment compared with those of the control group. These findings indicate that depletion of REV7 enhances sensitivity to cisplatin treatment in CCC, suggesting that REV7 is a candidate molecular target in CCC management. |
format | Online Article Text |
id | pubmed-4317831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BlackWell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-43178312015-10-05 Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells Niimi, Kaoru Murakumo, Yoshiki Watanabe, Naoki Kato, Takuya Mii, Shinji Enomoto, Atsushi Asai, Masato Asai, Naoya Yamamoto, Eiko Kajiyama, Hiroaki Shibata, Kiyosumi Kikkawa, Fumitaka Takahashi, Masahide Cancer Sci Original Articles Human REV7 (also known as MAD2L2 and MAD2B) is involved in DNA repair, cell cycle regulation, gene transcription, and carcinogenesis. In this study, we evaluated the expression of REV7 in epithelial ovarian cancer (EOC) and analyzed the association between its expression and chemosensitivity in ovarian clear cell carcinoma (CCC) cells. Expression of REV7 in human EOC tissues was assessed by immunohistochemical staining. Expression was detected in the majority of EOCs (92.0%) with especially high levels of expression frequently observed in CCCs (73.5%) compared with that of non-CCCs (53.4%). Enhanced immunoreactivity to REV7 was associated with poor prognosis represented by reduced progression-free survival in advanced stage (stage II–IV) EOC as assessed using Kaplan–Meier curves and log–rank tests. The effects of REV7 knockdown on cell proliferation and chemosensitivity in CCC cells were also analyzed in vitro and in vivo. Knockdown of REV7 in CCC cells decreased cell proliferation without affecting cell cycle distribution. Additionally, the number of apoptotic cells and DNA damaged cells were increased after cisplatin treatment. In a nude mouse tumor xenograft model, inoculated REV7-knockdown tumors showed significantly reduced tumor volumes after cisplatin treatment compared with those of the control group. These findings indicate that depletion of REV7 enhances sensitivity to cisplatin treatment in CCC, suggesting that REV7 is a candidate molecular target in CCC management. BlackWell Publishing Ltd 2014-05 2014-04-07 /pmc/articles/PMC4317831/ /pubmed/24597627 http://dx.doi.org/10.1111/cas.12390 Text en © 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Niimi, Kaoru Murakumo, Yoshiki Watanabe, Naoki Kato, Takuya Mii, Shinji Enomoto, Atsushi Asai, Masato Asai, Naoya Yamamoto, Eiko Kajiyama, Hiroaki Shibata, Kiyosumi Kikkawa, Fumitaka Takahashi, Masahide Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells |
title | Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells |
title_full | Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells |
title_fullStr | Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells |
title_full_unstemmed | Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells |
title_short | Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells |
title_sort | suppression of rev7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317831/ https://www.ncbi.nlm.nih.gov/pubmed/24597627 http://dx.doi.org/10.1111/cas.12390 |
work_keys_str_mv | AT niimikaoru suppressionofrev7enhancescisplatinsensitivityinovarianclearcellcarcinomacells AT murakumoyoshiki suppressionofrev7enhancescisplatinsensitivityinovarianclearcellcarcinomacells AT watanabenaoki suppressionofrev7enhancescisplatinsensitivityinovarianclearcellcarcinomacells AT katotakuya suppressionofrev7enhancescisplatinsensitivityinovarianclearcellcarcinomacells AT miishinji suppressionofrev7enhancescisplatinsensitivityinovarianclearcellcarcinomacells AT enomotoatsushi suppressionofrev7enhancescisplatinsensitivityinovarianclearcellcarcinomacells AT asaimasato suppressionofrev7enhancescisplatinsensitivityinovarianclearcellcarcinomacells AT asainaoya suppressionofrev7enhancescisplatinsensitivityinovarianclearcellcarcinomacells AT yamamotoeiko suppressionofrev7enhancescisplatinsensitivityinovarianclearcellcarcinomacells AT kajiyamahiroaki suppressionofrev7enhancescisplatinsensitivityinovarianclearcellcarcinomacells AT shibatakiyosumi suppressionofrev7enhancescisplatinsensitivityinovarianclearcellcarcinomacells AT kikkawafumitaka suppressionofrev7enhancescisplatinsensitivityinovarianclearcellcarcinomacells AT takahashimasahide suppressionofrev7enhancescisplatinsensitivityinovarianclearcellcarcinomacells |